Moderna Scraps Plans for mRNA Vaccine Plant in Japan Amid Weak Demand and Poor Business Environment.

Moderna Japan has canceled plans to build an mRNA vaccine plant at Shonan Health Innovation Park in Kanagawa prefecture due to weak demand for vaccines and a poor business environment. The company cited careful consideration in light of the current business environment, stating that they have decided not to proceed with the plan at this time.

Moderna Japan has announced the cancellation of its plans to build an mRNA vaccine plant at Shonan Health Innovation Park in Kanagawa prefecture. The decision, made in light of the current business environment, reflects a cautious approach to market demands and operational conditions. The company cited weak demand for vaccines and a challenging business environment as the primary reasons for the cancellation.

This development comes at a time when the global vaccine technologies market is experiencing significant growth, driven by advancements in mRNA, viral vector, and protein subunit vaccines. According to Coherent Market Insights, the market size is projected to reach USD 111.52 billion by 2032, with a compound annual growth rate (CAGR) of 10.0% from 2025 to 2032 [1].

The cancellation of the plant project is a strategic move by Moderna Japan, which aims to align its operational plans with current market conditions and business opportunities. The company has not ruled out the possibility of revisiting the project in the future, depending on changes in demand and market conditions.

The global vaccine technologies market is characterized by intense competition and rapid innovation. Key players such as Pfizer-BioNTech, Moderna, Johnson & Johnson, and AstraZeneca are investing heavily in R&D and expanding their manufacturing capabilities to meet the growing demand for effective vaccines. The market is expected to continue growing, driven by factors such as the rising incidence of infectious diseases, government funding, and technological advancements [1].

In conclusion, Moderna Japan's decision to cancel the mRNA vaccine plant project at Shonan Health Innovation Park is a strategic move based on current market conditions. The global vaccine technologies market, however, remains robust and is expected to continue growing, driven by advancements in vaccine platforms and increasing demand for effective disease prevention.

References:

[1] Coherent Market Insights. (2025). Vaccine Technologies Market. Retrieved from https://www.coherentmarketinsights.com/market-insight/vaccine-technologies-market-6150?utm_source=openpr.com&utm_medium=referral